Skip to main content

Table 1 Rheumatoid arthritis study population

From: Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity

Laboratory and clinical data

RA patients (n = 59)

Disease duration in days, mean ± SD

16 ± 11

Erosive RA, number (percentage)

54 (92)

Positive rheumatoid factor, >10 IU, ELISA, number (percentage)

52 (88)

Positive anti-CCP antibodies, >10 IU, ELISA, number (percentage)

52 (88)

ESR in mm/hour, mean ± SD; ESR >28, number (percentage)

28 ± 21; 35 (59)

CRP in mg/dL, mean ± SD; CRP >15, number (percentage)

25 ± 41; 23 (39)

DAS-28, mean ± SD

4.36 ± 1.7

   DAS-28 < 2.6, number (percentage)

11 (19)

   2.6 < DAS-28 < 5.1, number (percentage)

21 (35)

   DAS-28 > 5.1, number (percentage)

27 (46)

Methotrexate, number (percentage)

49 (83)

Low dose of prednisone, ≤10 mg/day, number (percentage)

54 (92)

Anti-tumor necrosis factor agents, number (percentage)

11 (17)

Anti-CD20 agents, number (percentage)

12 (20)

  1. anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS-28, 28-joint disease activity score; ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; SD, standard deviation.